Earnings summaries and quarterly performance for Annexon.
Executive leadership at Annexon.
Douglas Love
Detailed
President and Chief Executive Officer
CEO
JD
Jamie Dananberg
Detailed
EVP & Chief Medical Officer
JL
Jennifer Lew
Detailed
EVP & Chief Financial Officer
MO
Michael Overdorf
Detailed
EVP & Chief Business Officer
RA
Rick Artis
Detailed
EVP & Chief Scientific Officer
TY
Ted Yednock
Detailed
EVP & Chief Innovation Officer
Board of directors at Annexon.
Research analysts covering Annexon.
Recent press releases and 8-K filings for ANNX.
Annexon Updates Corporate Presentation for J.P. Morgan Healthcare Conference
ANNX
New Projects/Investments
Guidance Update
- Annexon, Inc. updated its corporate presentation on January 14, 2026, for the 44th Annual J.P. Morgan Healthcare Conference, detailing business and strategic updates.
- The company is advancing two flagship programs: Vonaprument (ANX007) for Dry AMD with Geographic Atrophy, with topline Phase 3 data anticipated in 2H 2026, and Tanruprubart (ANX005) for Guillain-Barré Syndrome, with an MAA submitted and an FDA BLA filing planned for 2026.
- 2026 is highlighted as a pivotal year for Annexon, with multiple catalysts and a cash runway into late 2027, aiming to unlock significant value in neuroinflammatory diseases.
Jan 14, 2026, 9:05 PM
Annexon Outlines Key 2026 Milestones and Market Opportunities
ANNX
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Annexon is advancing two lead programs, ANX007 for dry AMD with geographic atrophy and ANX005 for Guillain-Barré syndrome, which together address market opportunities exceeding $10 billion.
- Significant milestones for 2026 include the release of Phase 3 data for ANX007 in the second half of the year, anticipated FDA filing for ANX005 later in the year (following a recent European approval filing), and first proof of concept data for ANX1502.
- The company has funding secured into late 2027, extending more than a year beyond the ANX007 Phase 3 readout.
Jan 14, 2026, 7:15 PM
Annexon Outlines Key 2026 Milestones for Lead Programs
ANNX
Product Launch
New Projects/Investments
Guidance Update
- Annexon anticipates a pivotal year in 2026 with significant value creation opportunities from its lead programs.
- Phase III data for ANX007 in geographic atrophy, targeting a potential $7-$10 billion annual market, is expected in the second half of 2026.
- For ANX005 in Guillain-Barré syndrome, Annexon filed for European approval last week (prior to January 14, 2026) and anticipates filing with the FDA later in 2026.
- Proof of concept data for the oral small molecule ANX1502 in Cold Agglutinin Disease is also expected later in 2026.
- The company is funded into late 2027.
Jan 14, 2026, 7:15 PM
Annexon Biosciences Highlights 2026 as Pivotal Year for Late-Stage Pipeline
ANNX
New Projects/Investments
Product Launch
- Annexon Biosciences anticipates 2026 to be a pivotal year for significant value creation, driven by multiple catalysts from its late-stage assets.
- For Dry AMD with Geographic Atrophy, Vonaprument (ANX007) has topline Phase 3 data anticipated in 2H 2026 and targets a vision-preservation market with over $7 billion in global peak sales.
- Tanruprubart (ANX005), for Guillain-Barré Syndrome, has an EMA MAA filed, with an FDA BLA filing and initial FORWARD study data both planned for 2026.
- The company also expects proof-of-concept for ANX1502, its first oral C1 inhibitor for neuroinflammatory autoimmune diseases, in 2026.
- Annexon Biosciences is well-positioned with cash to fund anticipated key milestones into late 2027.
Jan 14, 2026, 7:15 PM
Annexon Provides Pipeline Updates and 2026 Milestones at JPMorgan Healthcare Conference
ANNX
Product Launch
New Projects/Investments
Guidance Update
- Annexon is advancing two lead blockbuster programs: ANX007 for geographic atrophy (GA) and ANX005 for Guillain-Barré syndrome (GBS).
- For ANX007 in GA, Phase 3 data is anticipated in the second half of 2026, with the potential to be the first vision-sparing therapy in a market opportunity estimated between $7-$10 billion annually.
- For ANX005 in GBS, the company filed for European approval last week and expects to file for FDA approval later in 2026, addressing a global patient population of 150,000.
- First proof of concept data for the mid-stage program, ANX1502, an oral small molecule for autoimmune conditions, is also expected later in 2026.
- Annexon is funded into late 2027.
Jan 14, 2026, 7:15 PM
Annexon Provides Updates on GBS, Geographic Atrophy, and Oral Program Timelines
ANNX
New Projects/Investments
Guidance Update
- Annexon is pursuing regulatory approval for its Guillain-Barré syndrome (GBS) program, with an anticipated submission in Europe by early January 2026 and later in the US in 2026. The company estimates a peak sales opportunity of $100,000 to $150,000 per course of therapy for 22,000-25,000 patients annually in the US and Europe.
- The Phase III program for Geographic Atrophy (GA) has completed enrollment with 650 patients and is expected to read out in the second half of 2026. This program is differentiated by its focus on significant vision preservation and protection of photoreceptor cells.
- Annexon's early-stage oral small molecule program, Annex 1502, targeting autoimmune conditions, is expected to have proof of concept data in 2026. This represents the first oral drug for a classical complement pathway.
- The company is actively discussing commercial partnerships for ex-US regions for its GBS program, while planning to commercialize in the US independently.
Nov 19, 2025, 8:30 AM
Annexon Provides Updates on GBS, Geographic Atrophy, and Small Molecule Programs
ANNX
Guidance Update
New Projects/Investments
Product Launch
- Annexon anticipates submitting for regulatory approval for its Guillain-Barré syndrome (GBS) program as early as January 2026 in Europe and later in 2026 in the US. The company estimates a market of 22,000-25,000 GBS patients between the US and Europe, with potential pricing between $100,000 and $150,000 for a course of therapy.
- The Phase III program for Geographic Atrophy (GA) is expected to read out in the second half of 2026. Annexon emphasizes its GA program's differentiation by targeting the source of neurodegenerative disease and demonstrating significant vision preservation.
- Data for Annexon's early translational proof of concept program, Annex 1502, a small molecule targeting autoimmune conditions, is also anticipated in 2026.
- Annexon is actively pursuing a commercial ex-US partnership for its GBS program, with discussions ongoing.
Nov 19, 2025, 8:30 AM
Annexon Provides Updates on GBS, Geographic Atrophy, and ANX1502 Programs
ANNX
Guidance Update
New Projects/Investments
Product Launch
- Annexon is pursuing regulatory approval for its Guillain-Barré syndrome (GBS) program, with submissions anticipated as early as January 2026 in Europe and later in 2026 in the U.S..
- The GBS program targets 22,000-25,000 patients annually in the U.S. and Europe, with analysts estimating peak sales of $100,000 to $150,000 per course of therapy.
- The U.S. regulatory path for GBS requires U.S. patient data due to an "America-first" policy, which Annexon is proactively addressing with an ongoing open-label study.
- Data from the phase III program for geographic atrophy (GA), which enrolled 650 patients, is expected in the second half of 2026.
- Proof-of-concept data for the early-stage ANX1502 oral small molecule program, targeting autoimmune conditions, is also anticipated in 2026.
Nov 19, 2025, 8:30 AM
Annexon prices $75 million public offering
ANNX
- Annexon, Inc. (ANNX) announced the pricing of an underwritten public offering, including 25,096,153 shares of common stock at $2.60 per share and 3,750,000 pre-funded warrants at a purchase price of $2.599 per share.
- The offering is expected to generate gross proceeds of $75 million for Annexon, before deducting underwriting discounts and other offering expenses.
- The offering is anticipated to close on November 14, 2025, and Annexon has granted the underwriters a 30-day option to purchase up to an additional 4,326,922 shares of common stock.
Nov 13, 2025, 3:55 AM
Annexon Commences Proposed Public Offering
ANNX
- Annexon, Inc. (NASDAQ: ANNX) commenced an underwritten public offering of its common stock or pre-funded warrants on November 12, 2025.
- The proposed offering is for $75 million of shares of common stock or pre-funded warrants.
- Annexon expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock.
- Goldman Sachs & Co. LLC, TD Cowen, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.
Nov 12, 2025, 9:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more